c-LEcta is a leading biotechnology company located in Leipzig, Germany. The company has established itself as a leading player in the realisation of high-value biotechnology products for regulated markets, either as in-house development or in close cooperation with the industry. c-LEcta innovation capability delivers cost-efficient and sustainable production processes, creating growth opportunities across existing and new markets.
This innovative biotechnology company was founded in 2012 as a spin-out of the Institute for Molecular Microbiology and Biotechnology of the Westfälische Wilhelms-Universität in Münster. Cysal is active in the production of biopolymers, peptides, and especially dipeptides. Furthermore, Cysal specializes in developing biotechnology solutions in General.
Hapila's counter-current crystallisation process provides a cost effective procedure for purification of active pharmaceutical ingredients, completed by experience in synthesis and particle design.
LOEWI GmbH is a scientific spin-off of the TU München with the mission to make personalized health and nutrition available to everyone by combining science and technology. LOEWI's patented personalization concept analyzes health relevant data of customers and patients, makes the analysis available via LOEWI's Health Profile (Medical Software Class I), and creates personalized nutrient recommendations and therapies using a sophisticated recommendation algorithm, which are 100% tailored to the personal needs of each customer and patient.
m2p-labs supplies microbioreactor systems focusing on micro fermentations and automated solutions for screening and bioprocess development. The product portfolio comprises high-throughput BioLector® micro fermentation systems, microtiter FlowerPlate® plates, and automated cultivation RoboLector® platforms, an integration of the BioLector® tool into a liquid handling system.
Proprietary online monitoring technology increases the number and the information content of microbial experiments, either aerobic, microaerophilic, or strictly anaerobic. Experiments can be conducted with excellent efficiency and high quality at low costs in microscale.
Numaferm developed a platform technology for fast, scalable and cost-efficient production of peptides and proteins, with a focus on pepteins (PEPTides & protEINS) in the range of 30-500 amino acids. They serve customers from pharma, biotech, agriculture, and cosmetics offering peptides and proteins at highest qualities, within weeks, in a sustainable way. In this context partnership deals with global CDMO PolyPeptide and the world’s leading animal health company Zoetis were closed.
Founded in 2017 as a spin-out of Düsseldorf University, Numaferm has grown to over 20 staff.